Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: West Pharmaceutical Services | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: West Pharmaceutical Services

Proprietary Products Segment sales grew 6% to $345.2 million in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

West Pharmaceutical Services
3Q Revenues: $456.1 million (+6%)
3Q Earnings: $56.3 million (+2%)
YTD Revenues: $1.4 billion (+6%)
YTD Earnings: $177.8 million (+15%)
Comments: Proprietary Products Segment sales grew 6% to $345.2 million. Biologics market unit sales growth was led by NovaPure, Daikyo and Flurotec components as well as products incorporating Daikyo’s Crystal Zenith technology. Generics market unit sales growth was led by sales of Daikyo components, products incorporating Crystal Zenith technology, self-injection platforms and Westar RU. Pharma market declines were due to the impact of a previously reported voluntary recall of our Vial2Bag product. Contract-Manufactured Products Segment sales grew 4% to $111.1 million led by sales of healthcare-related injection and diagnostic devices.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters